Healthequity (NASDAQ:HQY) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Monday, February 4th.
HQY has been the subject of a number of other reports. Wells Fargo & Co reduced their price objective on shares of Healthequity from $100.00 to $90.00 and set an “outperform” rating for the company in a report on Friday, December 7th. SunTrust Banks cut shares of Healthequity from a “buy” rating to a “hold” rating and reduced their price objective for the company from $105.00 to $90.00 in a report on Thursday, December 6th. Zacks Investment Research reissued a “buy” rating and set a $66.00 price target on shares of Healthequity in a research report on Monday, December 31st. Citigroup set a $102.00 price target on shares of Healthequity and gave the company a “buy” rating in a research report on Tuesday, January 8th. Finally, BidaskClub lowered shares of Healthequity from a “buy” rating to a “hold” rating in a research report on Friday, December 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $87.85.
NASDAQ:HQY traded up $2.80 during trading hours on Monday, reaching $83.28. The company had a trading volume of 660,704 shares, compared to its average volume of 787,779. The stock has a market capitalization of $5.02 billion, a price-to-earnings ratio of 154.22, a PEG ratio of 2.70 and a beta of 1.64. Healthequity has a twelve month low of $50.29 and a twelve month high of $101.58.
Healthequity (NASDAQ:HQY) last issued its quarterly earnings data on Tuesday, December 4th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. The firm had revenue of $70.50 million during the quarter, compared to analysts’ expectations of $69.60 million. Healthequity had a net margin of 24.52% and a return on equity of 12.42%. The business’s revenue was up 24.1% on a year-over-year basis. During the same period last year, the company earned $0.17 earnings per share. On average, research analysts forecast that Healthequity will post 0.91 EPS for the current year.
In other Healthequity news, VP Darcy G. Mott sold 4,000 shares of Healthequity stock in a transaction dated Thursday, December 20th. The shares were sold at an average price of $60.28, for a total value of $241,120.00. Following the sale, the vice president now owns 82,000 shares of the company’s stock, valued at $4,942,960. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Delano Ladd sold 6,875 shares of Healthequity stock in a transaction dated Wednesday, February 20th. The stock was sold at an average price of $78.00, for a total transaction of $536,250.00. Following the completion of the sale, the executive vice president now directly owns 14,340 shares in the company, valued at approximately $1,118,520. The disclosure for this sale can be found here. Insiders have sold 22,721 shares of company stock worth $1,599,038 over the last three months. 4.00% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in HQY. Legacy Financial Advisors Inc. bought a new stake in shares of Healthequity in the fourth quarter valued at approximately $28,000. MERIAN GLOBAL INVESTORS UK Ltd bought a new stake in shares of Healthequity in the fourth quarter valued at approximately $28,000. Duncker Streett & Co. Inc. bought a new stake in shares of Healthequity in the fourth quarter valued at approximately $30,000. Ffcm LLC bought a new stake in shares of Healthequity in the fourth quarter valued at approximately $122,000. Finally, Advisors Asset Management Inc. raised its position in shares of Healthequity by 57.4% in the second quarter. Advisors Asset Management Inc. now owns 2,136 shares of the company’s stock valued at $160,000 after purchasing an additional 779 shares during the period. 91.44% of the stock is currently owned by institutional investors and hedge funds.
Healthequity Company Profile
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading: Ex-Dividend
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.